Search results

7678 results

Sorted by Relevance . Sort by Date

  1. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1

  2. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  3. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell

  4. Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)

    Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults

  5. Jobs

    Jobs at NICE. Includes current vacancies, roles, location and salary information.

  6. Decision-making and mental capacity

    Everything NICE has said on decision-making for people who may, now or in the future, lack capacity to make their own decision in an interactive flowchart

  7. Decision making and mental capacity (QS194)

    This quality standard covers decision making in people aged 16 and over, using health and social care services who may lack capacity to make their own decisions (now or in the future). It aims to support implementation of the aims and principles of the Mental Capacity Act 2005 and relevant Codes of Practice. It is not a substitute for these.

  8. EBSCO

    Provider name: EBSCO Lot details Lot 1 - Databases, Aggregated Evidence Resource Summaries, Point of Care (PoC) Tools Lot 2 - Electronic

  9. Public health advisory committees

    Public health advisory committees (PHACs) are the standing committees responsible for the development of our public health guidance. Each committee...

  10. Into practice guide

    A selection of resources to help you deliver high-quality care and services using NICE guidance

  11. Get involved

    We want you to tell us what matters to you, your organisation or your community.

  12. Hepatitis B (chronic)

    Everything NICE has said on diagnosing and managing chronic hepatitis B in children, young people and adults in an interactive flowchart

  13. How to buy

    Jump to: Stages in the purchasing process Stage 1: draft and agree your purchasing requirements Stage 2: get approval to buy what you need Stage

  14. History of NICE

    1999 Creation of NICE The National Institute for Clinical Excellence became a legal entity in April. Our aim was to create consistent guidelines

  15. NICE Evidence Services issues

    The information below provides a summary of known issues and upcoming changes related to NICE Evidence Services. This information will be updated...

  16. Companies should specify patient populations in the NHS who could benefit from test-guided preventive care for acute kidney injury. Further research is then recommended in these populations to assess the clinical effectiveness of defined care bundles designed to prevent or reduce the effect of acute kidney injury in the NHS. Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population (see  section 4.11 ).

    Recommendation ID DG39/1 Question Companies should specify patient populations in the NHS who could benefit from test-guided preventive

  17. Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major safety concerns. However, evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.  Find out  what only in research means on the NICE website .

    Recommendation ID IPG676 Question Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises

  18. Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.  Find out  what special arrangements mean on the NICE website .

    Recommendation ID IPG674 Question Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited

  19. 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people who are having an acute exacerbation of their chronic condition and are unable to exercise, evidence of efficacy is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.   Find out  what standard arrangements mean on the NICE website . For people who are able to exercise, evidence on efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out  what only in research means on the NICE website .

    Recommendation ID IPG677 Question 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory

  20. Further research is recommended to assess the effect of test-guided preventive care (see section 5.1) on clinical outcomes (such as length of stay in hospital, mortality and need for renal replacement therapy and progression to chronic kidney disease). Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population. Studies should investigate the effects of both positive and negative test results on clinical decisions and subsequent care.

    Recommendation ID DG39/2 Question Further research is recommended to assess the effect of test-guided preventive care (see section 5.1)

  21. Do the direct anterior, direct superior and supercapsular percutaneously assisted (SuperPATH) approaches to hip replacement improve patient-recorded outcome measures and reduce length of hospital stays, revision rates, neurological complications and surgical site infections compared with the posterior and anterolateral approaches?

    Recommendation ID NG157/11 Question Do the direct anterior, direct superior and supercapsular percutaneously assisted (SuperPATH) approaches

  22. COVID-19 rapid guideline: dialysis service delivery (NG160)

    The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.

  23. Endorsement

    Formally endorses resources produced by external organisations that support the implementation of NICE guidance and the use of quality standards.